Here are seven points:
1. Implanet’s spine activity saw growth in 2015, due to pediatric scoliosis market share gains and an increased use of the JAZZ platform for degenerative spinal disorders.
2. The company’s spine revenue increased 45 percent in 2015 to about €2.8 million.
3. The company’s spine sector composed 42 percent of Implanet’s total sales in 2015, compared to 27 percent in 2014.
4. Implanet spent €1.5 million to expand its reach in the U.S. market. It also boosted its distribution of JAZZ in Europe and Latin America.
5. The company experienced an operating loss of €7.6 million and a net loss of €8 million.
6. In 2015, the company had cash and financial investments totaling €7.1 million.
7. Implanet will focus on clinical and operational strategies in 2016.
More articles on devices:
Ghost Tree Capital buys 55k shares of NuVasive: 3 points
5 trends in the Japanese knee replacement devices market — Zimmer Biomet, Stryker in the lead
FDA clears Xtant’s Xspan Laminoplasty Fixation System — 4 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
